

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2026-412US1	SERIAL NO. 08/417,714
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT <div style="text-align: center;">Kawakami And Rosenberg</div>	
		FILING DATE April 5, 1995	GROUP 1813

PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SJH		5 2 6 2 1 7 7	11/16/93	Brown et al.	—		
↓		5 3 4 2 7 7 4	08/31/94	Boon et al.	—		

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
SJH		0 6 6 8 3 5 0	08/23/95	EPO	—		
↓		3 3 4 1 3 6 7	05/24/84	GERMANY (DE)	—		
↓		2 1 3 3 5 4 3	08/25/84	GB	—		
↓		9 5 2 2 5 6 1	08/24/95	PCT	—		
↓		9 4 2 3 0 6 7	10/13/94	PCT	—		
↓		9 3 1 4 1 8 9	07/22/93	PCT	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

SJH		Coulie, P.G. et al. (1993) "Genes coding for tumor antigens recognized by human cytolytic T-lymphocytes" <i>J. Immunotherap.</i> 14:104-109
↓		Coulie P.G. et al. "A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas". <i>J. Exp Med</i> (1994) 180:35-42
↓		Mareah, C.A. et al.: Cloning and expression of the gene for the melanoma associated ME20 antigen. <i>DNA and Cell Biology</i> , 1994; 13:87-95
↓		Cox, A.L., et al. "Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines" <i>Science</i> 1994; 264:716-719.
↓		Brichard, V., et al.: "The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas". <i>J. Exp. Med.</i> 1993; 178:489-495.
↓		Gaugler, B., et al. "Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes". <i>J. Exp. Med.</i> 1994; 179:921-930.

571		Traversari, C., et al.: "A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E". <i>J. Exp. Med.</i> 1992; 176:1453-1457.
		Cellis, E., et al.: "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptides epitopes". <i>Proc. Natl. Acad. Sci. U.S.A.</i> 1994; 91:2105-2109.
		Boon, T.: "Toward a genetic analysis of tumor rejection antigens". <i>Adv. Cancer Res.</i> 1992; 58:177-210.
		Kawakami, Y., et al.: T-cell recognition of human melanoma antigens. <i>J. Immunother.</i> 1993; 14:88-93.
		Bakker, A.B.H., et al.: Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor infiltrating lymphocytes. <i>J. Exp. Med.</i> 1994; 179:1005-1009.
		Wölfel, T., et al.: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. <i>Eur. J. Immunol.</i> 1994; 24:759-764.
		Adema, G.J., et al.: Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. <i>Am. J. Pathol.</i> 1993; 143:1579-1585.
		Kwon, B.S., et al.: A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. <i>Proc. Natl. Acad. Sci. USA</i> 1991; 88:9228-9232.
		Rosenberg, S.A., et al.: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. <i>N. Engl. J. Med.</i> 1988; 319:1676-1680.
		Kawakami, Y., et al.: Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2 transfected melanomas. <i>J. Immunol</i> 1992; 148:638-643.
		Van der Bruggen, et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. <i>Science</i> 1991; 254:1643-1647.
		Falk, K., et al.: "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules." <i>Nature</i> 1991, 351:290-296.
		Kubo, R., et al.: "Definition of specific peptide motifs for four major HLA-A Alleles." <i>Journal of Immunology</i> 1994, 152:3913-3924.
		Parker, K., et al.: "Sequence motifs important for peptide binding to the human MHC class I molecule. HLA-A2." 1992, <i>J. Immunol</i> :3580-3587.
		Ruppert, J., et al.: "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules." <i>Cell</i> 1993, 74:929-937.
		Storkus, W., et al.: "Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes." <i>Journal of Immunology</i> 1993, 151:3719-3727.
		Kawakami, Y., et al.: "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor." <i>Proc. Natl. Acad. Sci. USA</i> 1994, 91:3515-3519.
		Adema, G.J. et al., "Molecular characterization of the melanocyte lineage-specific antigen gp100." <i>Journal of Biological Chemistry</i> 1994, 269:20126-20133.
		EMBL DATABASE ACCESSION NUMBER M32295:26-11-90 Vogel A.: Human KD melanocyte specific secreted glycoprotein mRNA 3'end'
		Kawakami, Y., et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with <i>in vivo</i> tumor rejection" <i>PNAS</i> 91:6458-6462 1994
		Kawakami, Y., et al., "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes" <i>J. Exp. Med.</i> 180:347-352, 1994
		Rivoltini, L., et al., "Induction of Tumor-Reactive CTL from Peripheral Blood and Tumor-Infiltrating Lymphocytes of Melanoma Patients by In Vitro Stimulation with an Immunodominant Peptide of the Human Melanoma Antigen MART 1" <i>Journal of Immunology</i> , 1995, 154:2257-2265
		Slingluff, C.L., Jr., et al., "Direct analysis of tumor-associated peptide antigens" <i>Current Opinion in Immunology</i> 1994 6:733-740

574			Cole, D.J., et al., "Characterization of the Functional Specificity of a Cloned T-Cell Receptor Heterodimer Recognizing the MART-1 Melanoma Antigen" <i>Cancer Res.</i> 55:748-752 Feb. 1995
			Cole, D.J., et al., "Identification of MART-1-specific T-Cell Receptors: T Cells Utilizing Distinct T-Cell Receptor Variable and Joining Regions Recognize the Same Tumor Epitope" <i>Cancer Res.</i> 54:5265-5268, 1994
			Castelli, C., et al., "Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8 ⁺ Cytotoxic T Lymphocytes" <i>J. Exp. Med.</i> 181:363-368 1995
			Sette, A., et al., "Peptide Binding To The Most Frequent HLA-A Class I Alleles Measured By Quantitative Molecular Binding Assays" <i>Molecular Immunology</i> 31:813-822, 1994
			Wölfel, T., et al., "Analysis Of Antigens Recognized On Human Melanoma Cells By A2-Restricted Cytolytic T Lymphocytes (CTL)" <i>Int. J. Cancer</i> 55:237-244, 1993.
			Wölfel, T., et al., "Isolation Of Naturally Processed Peptides Recognized By Cytolytic Lymphocytes (CTL) On Human Melanoma Cells In Association With HLA-A2.1" <i>Int. J. Cancer</i> 57:413-418, 1994.
			Topalian, S.L., et al., "Human CD4 ⁺ T Cells Specifically Recognize a Shared Melanoma-Associated Antigen Encoded by the Tyrosinase Gene" <i>PNAS</i> 91:9461-9465, 1994.
			Boël, P., et al., "BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes" <i>Immunology</i> 2:167-175 1995
			Slingluff, C.L., Jr., et al., "Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocyte Is Mediated by at Least Six Shared Peptide Epitopes" <i>Journal of Immunology</i> 150:2955-2963 1993
			GENBANK DATABASE ACCESSION NUMBER M77348 - Human PMEL 17 in RNA - January 8, 1995
			GENBANK DATABASE ACCESSION NUMBER U06654 - Human Differentiation Antigen Melan-A Protein in RNA - July 30, 1994
			GENBANK DATABASE ACCESSION NUMBER U06452 - Human Melanoma Antigen Recognized by T-Cells (MAR7-1) MRNA - June 25, 1994
			GENBANK DATABASE ACCESSION NUMBER S73003 - GP100 Melanocyte Lineage Specific Antigen / PMEL 17 January 25, 1995
			GENBANK DATABASE ACCESSION NUMBER U01874 - Human ME20 MRNA May 27, 1994


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-FB-AB20
also form PTO-1449)

Patent and Trademark Office - U.S. DEPARTMENT of COMMERCE



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	1
-------	---	----	---

Application Number	09/898,860
Filing Date	July 3, 2001
First Named Inventor	Yutaka Kawakami
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	218748

[illegible][illegible]

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No++
SH		Cohen, <i>Science</i> , 262, 841 (1993)		
↓		<i>Webster's New Riverside Dictionary</i> , p. 365 (1984)		

Miss

10	24	03
----	----	----

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).